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Ischemic heart disease is the leading cause of death in 
developed nations. Extending myocardial ischemic toler-
ance could be a promising strategy to improve patient out-
come after acute cardiovascular events. Volatile anesthetics 
such as isoflurane, desflurane, and sevoflurane confer car-
dioprotection by inducing preconditioning1-3 and postcon-
ditioning.4-6 Postconditioning might be of exceptional 
relevance in the clinical setting since myocardial ischemia 
usually is unpredictable, very much limiting the use of pre-
conditioning. Improved outcome via pharmaceutical post-
conditioning is indisputable in animal studies but difficult 
to detect in patients.7 Various mechanisms, such as age, 
comorbidities, and the accompanying pharmacotherapy, 
can interfere with cardioprotection, thus presenting a chal-
lenge for successful clinical translation.
Inhibitors of cyclooxygenase (COX)-1 and -2 are 
widely prescribed because of their anti-inflammatory and 
analgesic properties. However, application of COX-2 
inhibitors is critical in patients with a high cardiovascular 
risk profile.8-10 In particular, administration of valdecoxib 
and its oral prodrug parecoxib was associated with serious 
cardiovascular events after coronary artery bypass graft 
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Abstract
Cyclooxygenase (COX)-2 mediates ischemic pre- and postconditioning as well as anesthetic-induced preconditioning. 
However, the role of COX-1 and -2 in anesthetic-induced postconditioning has not been investigated. We evaluated 
the role of COX-1 and -2 in sevoflurane-induced postconditioning in vivo. Pentobarbital-anaesthetized male C57BL/6 
mice were subjected to 45 minutes of coronary artery occlusion and 3 hours of reperfusion. Animals received either 
no intervention, the vehicle dimethyl sulfoxide (DMSO, 10 µL/g intraperitoneally), acetylsalicylic acid (ASA, 5 µg/g 
intraperitoneally), the selective COX-1 inhibitor SC-560 (10 µg/g intraperitoneally), or the selective COX-2 inhibitor NS-
398 (5 µg/g intraperitoneally). 1.0 MAC (minimum alveolar concentration) sevoflurane was administered for 18 minutes 
during early reperfusion either alone or in combination with ASA, SC-560, and NS-398. Infarct size was determined 
with triphenyltetrazolium chloride. Statistical analysis was performed using 1-way and 2-way analyses of variance with 
post hoc Duncan testing. The infarct size in the control group was 44% ± 9%. DMSO (42% ± 7%), ASA (36% ± 6%), and 
NS-398 (44% ± 18%) had no effect on infarct size. Sevoflurane (17% ± 4%; P < .05) and SC-560 (26% ± 10%; P < .05) 
significantly reduced the infarct size compared with control condition. Sevoflurane-induced postconditioning was not 
abolished by ASA (16% ± 5%) and SC-560 (22% ± 4%). NS-398 abolished sevoflurane-induced postconditioning (33% ± 
14%). It was concluded that sevoflurane induces postconditioning in mice. Inhibition of COX-1 elicits a myocardial infarct 
size reduction and does not abolish sevoflurane-induced postconditioning. Blockade of COX-2 abolishes sevoflurane-
induced postconditioning. These results indicate that sevoflurane-induced postconditioning is mediated by COX-2.
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surgery.10 Therefore, some of the COX-2 inhibitors were 
taken off the market or were not approved in several coun-
tries. In the experimental setting, COX-2 inhibitors abolish 
the acute phase of ischemic and volatile anesthetic-induced 
preconditioning against myocardial infarction, indicating 
an important role for COX-2 in cardioprotection.1
Whether cyclooxygenase enzymes 1 and 2 play a role 
in the signal transduction cascade of anesthetic-induced 
postconditioning has not been investigated to date. Hence, 
we tested the hypothesis that blockade of COX-1 and -2 
abolishes sevoflurane-induced postconditioning in the 
murine heart in vivo.
Methods
Ethical Approval
All experimental procedures used in this investigation 
were reviewed and approved by the Animal Care and Use 
Committee of the Government of Lower Franconia, 
Bavaria, Germany. All experiments were in accordance 
with the Guide for the Care and Use of Laboratory 
Animals11 and conformed to the Guiding Principles in the 
Care and Use of Animals of the American Physiological 
Society.
Animals
Male C57BL/6 mice (8-12 weeks old) were purchased 
from Harlan (Horst, The Netherlands). Animals were 
housed under controlled conditions (22°C, 55%-65% 
humidity, 12-hour light-dark cycle) and were allowed free 
access to water and a standard laboratory chow.
Instrumentation and Surgical Procedures
Instrumentation and surgical procedures were performed 
as described previously.12,13 Briefly, mice were anesthe-
tized with an intraperitoneal injection of 60 µg/g sodium 
pentobarbital (Merial, Hallbergmoos, Germany), and 
repeated intraperitoneal injections were given as needed to 
maintain anesthesia. Rectal temperature was maintained at 
37.0°C ± 0.1°C using a servo-controlled heating pad (FMI, 
Seeheim, Germany). After intubation of the trachea, mice 
were ventilated with a 50%/50% air-oxygen mixture using 
a small rodent ventilator (SAR-P 830, CWE Inc, Ardmore, 
Pennsylvania) operating in pressure-controlled mode. A 
3-lead needle-probe electrocardiogram (ECG) was 
attached to continuously monitor heart rate and ST-segment 
elevation. Saline-filled polyethylene catheters were placed 
into the right common carotid artery for measurement of 
mean arterial blood pressure and into the right jugular vein 
for continuous fluid administration (20 µL/g/h). A left tho-
racotomy at the fourth intercostal space was performed, 
and the left anterior descending coronary artery (LAD) 
was exposed. The ligature was set as previously described.12 
Coronary artery occlusion was achieved using the hanging 
weight system14 and was verified by ECG ST-segment 
elevation and paleness of the myocardial area at risk 
(AAR). Adequate reperfusion was verified by epicardial 
hyperemia and reversion of ECG changes.
Experimental Protocol
After completion of surgical procedures, investigators ran-
domly assigned mice to 1 of the 9 study groups by opening 
a sealed envelope containing information about the study 
group. Group size was n = 7 in each group. The experi-
mental protocol is illustrated in Figure 1.
All mice were allowed a 30-minute equilibration period. 
Myocardial ischemia was induced by 45 minutes of coro-
nary artery occlusion (CAO) followed by 3 hours of reper-
fusion. Control animals (CON) received no treatment 
before CAO. In group 2 (DMSO), the vehicle dimethyl 
sulfoxide (DMSO, 10 µL/g) was injected intraperitoneally 
(i.p.) 10 minutes prior to the end of CAO. In group 3 
(SEVO), 1.0 MAC (minimum alveolar concentration, 3,4 
Vol-%15) sevoflurane was given for 18 minutes starting 3 
minutes prior to the end of CAO. Sevoflurane concentra-
tion was gradually increased from 0.0 to 1.0 MAC and 
gradually decreased from 1.0 MAC to 0.0 MAC over a 
time period of 2 minutes. Ten minutes prior to the end of 
CAO, animals received the nonselective COX inhibitor 
acetylsalicylic acid (ASA, 5 µg/g) either alone (ASA) or in 
combination with sevoflurane (SEVO+ASA). To evaluate 
the role of COX-1, the selective COX-1 inhibitor SC-560 
(10 µg/g16) was given i.p. 10 minutes prior to the end of 
CAO, either alone (SC-560) or in combination with sevo-
flurane (SEVO+SC-560). The selective COX-2 inhibitor 
NS-398 (5 µg/g16) was administered i.p. either alone (NS-
398) or in combination with sevoflurane (SEVO+NS-398) 
to investigate the role of COX-2 in sevoflurane-induced 
postconditioning.
Measurement of Myocardial Infarct Size
Myocardial infarct size (IS) and area at risk (AAR) were 
determined using methods previously described.12 Briefly, 
after 3 hours of reperfusion, the LAD was reoccluded and 
1 mL of Evans Blue (0.1 g/mL, Sigma-Aldrich, 
Taufkirchen, Germany) was slowly injected into the 
carotid artery. After intraperitoneal injection of a lethal 
dose of sodium pentobarbital (150 µg/g), the heart was 
rapidly excised. The left ventricle was separated and cut 
into 7 or 8 transversal slices of each 1 mm thickness. Slices 
were incubated in 2,3,5-triphenyltetrazolium chloride (20 
mg/mL) for 30 minutes at 37°C. After overnight fixation in 
10% formaldehyde, slices were weighted and digitally 
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photographed. Photographs were analyzed using 
AdobePhotoshop CS 8.0.1 (Adobe Systems Inc, San Jose, 
California), and the normal zone, AAR, and IS were deter-
mined gravitoplanimetrically by a blinded investigator. 
Animals with an AAR of less than 20% were excluded 
from the study.
Data Acquisition and Statistical Analysis
ECG, systemic hemodynamic parameters, and body tem-
perature were continuously recorded and analyzed on a 
personal computer (Fujitsu Siemens, Augsburg, Germany) 
using a hemodynamic data acquisition and analysis soft-
ware (Notocord hem 3.5, Croissy sur Seine, France).
Drawing from other studies on the same experimental 
model, we expected a myocardial IS between 45% and 
50% (IS/AAR). Power analysis revealed a group size of 
n = 7 to detect a difference in means of 20% with a power 
of 0.8 at a α-level of 0.05. Statistical analyses were done 
by analyses of variance (ANOVAs), which were based on 
2-tailed F tests for comparison of components of the fac-
tors’ total deviation. Analysis for body weight, left ventri-
cle weight, left ventricle weight/body weight, AAR, IS, IS/
left ventricle weight, and AAR/left ventricle weight was 
performed using 1-way ANOVA including the factor treat-
ment (CON vs DMSO vs SEVO vs ASA vs SEVO+ASA 
vs SC-560 vs SEVO+SC-560 vs NS-398 vs SEVO+NS-398) 
and post hoc Duncan’s test for significant main effects and 
interactions. Analysis of hemodynamic data was per-
formed by a 9 × 7 ANOVA for repeated measures, includ-
ing the between-factor treatment (CON vs DMSO vs 
SEVO vs ASA vs SEVO+ASA vs SC-560 vs 
SEVO+SC-560 vs NS-398 vs SEVO+NS-398) and the 
within-factor time point (baseline vs pre-CAO vs CAO vs 
Figure 1. Schematic diagram illustrating the experimental protocol. CAO is coronary artery occlusion. CON, control group. 
DMSO, dimethyl sulfoxide (10 µL/g) intraperitoneally (i.p.) 10 minutes prior to the onset of reperfusion. SEVO, 1.0 MAC (minimum 
alveolar concentration) sevoflurane for 18 minutes starting 3 minutes prior to the onset of reperfusion. ASA, acetylsalicylic acid (5 
µg/g) i.p. 10 minutes prior to the onset of reperfusion. SEVO+ASA, acetylsalicylic acid (5 µg/g) i.p. 7 minutes prior to sevoflurane (1.0 
MAC). SC-560, SC-560 (10 µg/g) i.p. 10 minutes prior to the onset of reperfusion. SEVO+SC-560, SC-560 (10 µg/g) i.p. 7 minutes 
prior to sevoflurane (1.0 MAC). NS-398, NS-398 (5 µg/g) i.p. 10 minutes prior to the onset of reperfusion. SEVO+NS-398, NS-398 
(5 µg/g) i.p. 7 minutes prior to sevoflurane (1.0 MAC).
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post-CAO vs reperfusion for 60 minutes vs reperfusion for 
120 minutes vs reperfusion for 180 minutes). In case of 
any significant main effects or interactions, post hoc 1-way 
ANOVAs were conducted for each group and each time 
point. Statistical analysis of data was performed using 
SPSS 19.0 software (The Apache Software Foundation, 
Forest Hill, Maryland). Changes in means were considered 
statistically significant when P < .05. Data are presented as 
mean ± standard deviation (SD).
Results
Overall, 68 mice were included in the study to obtain 63 
successful experiments. Five animals were excluded 
because of pump failure during CAO (2 in the 
SEVO+SC-560 group, 1 in the NS-398 group, 1 in the 
SEVO+NS-398 group) or because the AAR was less than 
20% (1 in the SEVO+SC-560 group).
Hemodynamic Parameters and AAR
Hemodynamic parameters at baseline and AAR were not 
different among groups (Tables 1 and 2 and Figure 2). 
Compared with baseline values, the heart rate was 
decreased during the administration of sevoflurane, 
although statistical significance was only observed in the 
SEVO and the SEVO+ASA groups. It was not present if 
sevoflurane was administered in combination with SC-560 
or NS-398. Mean arterial pressure (MAP) was signifi-
cantly decreased during CAO compared with the respec-
tive baseline values in the DMSO and SEVO+NS-398 
groups. During sevoflurane administration, MAP was sig-
nificantly decreased in the SEVO+SC-560 group.
Myocardial Infarct Size
Myocardial infarct size (IS/AAR) was 44% ± 9% in the 
control group (Figures 3 and 4). Neither the vehicle 
dimethyl sulfoxide (DMSO; 42% ± 7%) nor the nonselec-
tive COX inhibitor acetylsalicylic acid (ASA; 36% ± 6%) 
alone altered the resulting infarct size. Application of 1.0 
MAC sevoflurane during early reperfusion significantly 
reduced the ischemic injury compared with control ani-
mals (SEVO; 17% ± 4%). The nonselective COX inhibitor 
ASA did not abolish sevoflurane-induced postcondition-
ing (SEVO+ASA; 16% ± 5%). Inhibition of COX-1 using 
the selective inhibitor SC-560 reduced the IS to 26% ± 
10% (SC-560) while not affecting sevoflurane-induced 
Table 1. Systemic Hemodynamic Parameters.a
Reperfusion
 BL Pre-CAO CAO Post-CAO 60 min 120 min 180 min
Heart rate, min-1
CON 459 ± 55 453 ± 58 450 ± 59 432 ± 37 448 ± 31 435 ± 30 444 ± 32
DMSO 466 ± 33 474 ± 18 459 ± 35 466 ± 48 460 ± 33 458 ± 19 461 ± 49
SEVO 462 ± 18 462 ± 11 452 ± 34 406 ± 36b 433 ± 31 436 ± 20 438 ± 19
ASA 468 ± 32 460 ± 38 449 ± 21 457 ± 35 430 ± 36 436 ± 36 454 ± 31
SEVO+ASA 463 ± 47 461 ± 46 441 ± 25 401 ± 42b 435 ± 46 456 ± 65 433 ± 33
SC-560 457 ± 35 467 ± 35 468 ± 34 482 ± 53 466 ± 36 468 ± 46 472 ± 20
SEVO+SC-560 493 ± 23 491 ± 58 470 ± 46 420 ± 45 473 ± 33 470 ± 22 461 ± 32
NS-398 461 ± 32 464 ± 35 466 ± 27 467 ± 58 478 ± 38 470 ± 24 475 ± 43
SEVO+NS-398 471 ± 12 478 ± 25 469 ± 31 433 ± 41 470 ± 39 473 ± 31 472 ± 39
Mean arterial pressure, mm Hg
CON 75 ± 3 74 ± 7 60 ± 4 67 ± 5 67 ± 8 67 ± 12 67 ± 13
DMSO 68 ± 7 64 ± 6 60 ± 9b 67 ± 11 67 ± 9 68 ± 9 67 ± 5
SEVO 68 ± 7 68 ± 6 58 ± 7 64 ± 5 62 ± 6 66 ± 9 64 ± 8
ASA 69 ± 10 65 ± 9 61 ± 4 68 ± 4 68 ± 6 67 ± 7 69 ± 6
SEVO+ASA 73 ± 11 72 ± 12 62 ± 8 60 ± 8 71 ± 16 65 ± 9 71 ± 17
SC-560 69 ± 13 69 ± 12 57 ± 11 65 ± 17 63 ± 11 59 ± 4 66 ± 10
SEVO+SC-560 72 ± 5 69 ± 6 66 ± 6 58 ± 6b 61 ± 6 68 ± 9 62 ± 7
NS-398 74 ± 4 75 ± 4 68 ± 7 72 ± 14 70 ± 13 70 ± 10 69 ± 8
SEVO+NS-398 78 ± 6 76 ± 7 65 ± 7b 63 ± 14 73 ± 17 72 ± 6 69 ± 9
Abbreviations: ASA, acetylsalicylic acid; BL, baseline; CAO, coronary artery occlusion; CON, control; DMSO, dimethyl sulfoxide; NS-398, a selective 
cyclooxygenase-2 inhibitor; SC-560, a selective cyclooxygenase-1 inhibitor; SEVO, sevoflurane.
aData are mean ± SD. Data were analyzed at the end of the baseline period; before, during, and after CAO; and 60, 120, and 180 minutes after the 
onset of reperfusion as indicated by triangles in Figure 1.
bSignificantly (P < .05) different from baseline.
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postconditioning (SEVO+SC-560; 22% ± 4%). The selec-
tive COX-2 inhibitor NS-398 alone did not affect myocar-
dial IS (NS-398; 44% ± 18%) but abolished the protective 
effects provided by sevoflurane-induced postconditioning 
(SEVO+NS-398; 33% ± 14%).
Discussion
The present study investigates the role of both cyclooxy-
genase-1 (COX-1) and cyclooxygenase-2 (COX-2) in 
sevoflurane-induced postconditioning (APOC) against 
myocardial infarction using a murine in vivo model. The 
results demonstrate a major role for COX-2 within the sig-
nal transduction pathway of APOC, whereas COX-1 is dis-
pensable in this model.
The volatile anesthetic sevoflurane was administered 
during early reperfusion after coronary artery occlusion 
and conferred cardioprotection as reflected by a pro-
nounced reduction in myocardial infarct size compared 
with control animals. Sevoflurane-induced postcondition-
ing (APOC) reduces myocardial infarct size up to 60% in 
this mouse model. Cardioprotection by APOC has been 
described in different species and models, such as in iso-
lated rat hearts,17 and in the rat18 and rabbit myocardium in 
Table 2. Body Weight and Planimetry.a
n BW, g LV, mg LV/BW, % AAR, mg IS, mg IS/LV, % AAR/LV, %
CON 7 25.3 ± 2.0 70.4 ± 7.9 0.28 ± 0.02 23.0 ± 9.7 10.0 ± 4.5 13.9 ± 5.0 32.1 ± 11.2
DMSO 7 25.3 ± 3.4 76.1 ± 7.2 0.30 ± 0.02 24.5 ± 8.2 10.2 ± 3.6 13.3 ± 4.5 32.3 ± 11.5
SEVO 7 25.1 ± 1.6 69.8 ± 7.6 0.28 ± 0.02 23.7 ± 5.1 3.9 ± 1.1b 5.6 ± 1.5b 34.1 ± 7.3
ASA 7 25.1 ± 2.2 72.9 ± 9.5 0.29 ± 0.02 22.0 ± 4.9 7.8 ± 2.3 10.9 ± 3.0 30.3 ± 5.5
SEVO+ASA 7 25.1 ± 2.9 68.2 ± 8.7 0.27 ± 0.03 21.0 ± 4.8 3.5 ± 1.6b 5.1 ± 1.7b 30.5 ± 4.5
SC-560 7 25.0 ± 2.2 72.5 ± 9.2 0.29 ± 0.04 20.2 ± 5.0 5.5 ± 3.1b 7.3 ± 3.7b 27.6 ± 3.7
SEVO+SC-560 7 27.0 ± 2.4 77.5 ± 5.9 0.29 ± 0.02 27.6 ± 4.7 6.1 ± 1.4b 8.0 ± 2.0b 35.6 ± 5.4
NS-398 7 26.0 ± 1.9 73.3 ± 4.4 0.28 ± 0.02 22.2 ± 6.1 9.6 ± 4.6 13.3 ± 6.6 30.2 ± 7.5
SEVO+NS-398 7 24.6 ± 2.1 73.5 ± 5.7 0.30 ± 0.02 28.7 ± 9.6 9.3 ± 4.0 12.7 ± 5.8 39.4 ± 14.8
Abbreviations: AAR, area at risk; ASA, acetylsalicylic acid; BW, body weight; CON, control; DMSO, dimethyl sulfoxide; IS, infarct size; LV, left 
ventricle; NS-398, a selective cyclooxygenase-2 inhibitor; SC-560, a selective cyclooxygenase-1 inhibitor; SEVO, sevoflurane.
aData are mean ± SD.
bSignificantly (P < .05) different from CON.
Figure 2. Mean values of heart rate (HR) and mean arterial pressure (MAP). For better visibility, standard deviations and indicators 
of significance are not shown. Please refer to Table 1 for further information. Data were analyzed at the end of the baseline period 
(BL); before (PreCAO), during (CAO), and after (POST) coronary artery occlusion; and 60, 120, and 180 minutes after the onset of 
reperfusion (Rep60, Rep120, and Rep180). ASA, acetylsalicylic acid; CON, control; DMSO, dimethyl sulfoxide; NS-398, a selective 
cyclooxygenase-2 inhibitor; SC-560, a selective cyclooxygenase-1 inhibitor; SEVO, sevoflurane.
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vivo.19 Former studies in a murine model reported an 
infarct size reduction of up to 70%.20 Redel et al20 demon-
strated that sevoflurane-induced postconditioning was as 
effective as ischemic postconditioning and sevoflurane-
induced pre-conditioning.20 The current results confirm 
the previously reported data regarding the cardioprotective 
ability of sevoflurane-induced postconditioning in mice.
The results further indicate an important role of COX-2 
within the signal transduction cascade of sevoflurane-
induced postconditioning. We used NS-398 at a dose that 
was previously shown to sufficiently block COX-2 in 
mice.16 The isoform COX-2 is known to be an important 
mediator of early and delayed ischemic1,21 and anesthetic-
induced1,22 preconditioning. Additionally, other studies 
indicate a major role of COX regarding ischemic23 and 
anesthetic-induced24 postconditioning. Particularly, COX-2 
appears essential regarding reperfusion injury in mam-
mals25 and preconditioning by noble gases.26,27 The results 
of the current study are in line with these results, indicating 
the indispensability of COX-2 in the signaling cascade of 
sevoflurane-induced postconditioning. In rats, ischemic 
postconditioning was shown to be COX-2 dependent since 
the selective COX-2 inhibitor celecoxib abolished the 
infarct-sparing effect of combining late ischemic precondi-
tioning with postconditioning.28 The authors suggested that 
postconditioning enhances the enzymatic activity of 
COX-2 induced via late preconditioning. The results of the 
current study are in line with these results, demonstrating 
that sevoflurane-induced postconditioning is dependent on 
COX-2-activity.
Anesthetic-induced postconditioning is a very complex 
phenomenon that depends on the activation of many intra-
cellular targets. The exact signaling mechanisms are not 
completely understood. It is known that volatile anesthet-
ics activate several prosurvival kinases such as PI3K/Akt 
and Erk1/2, which in turn prevents the formation of pro-
apoptotic proteins.29 This cascade has been named the 
reperfusion injury salvage kinase (RISK) pathway.30 The 
protective cascades converge to the mitochondria and 
reduce the opening probability of the mitochondrial per-
meability transition pore (mPTP).31 This preserves mito-
chondrial and cellular integrity.
Furthermore, selective inhibition of COX-1 was cardio-
protective in this model. Myocardial infarct size was 
reduced to an extent similar to that achievable with APOC. 
This finding is remarkable since earlier studies were not 
able to demonstrate this effect.16,32 SC-560 as the COX-1 
inhibitor was used at a dose that recently has been demon-
strated to effectively block COX-1 in the murine heart dur-
ing I/R-injury.16 Potential unselective intrinsic effects of 
SC-560 on other components in the signaling cascade thus 
remain speculative. However, SC-560 is a frequently used 
inhibitor in rodent reperfusion-injury studies, and other 
selective COX-1 inhibitors like FR12204733 and mofezo-
lac34 have not been tested. One might further speculate that 
selective COX-1 inhibition leads to a shift of the throm-
boxane/prostaglandin balance toward the prostaglandins, 
which in turn causes vasodilatation of coronary arteries. 
This might result in increased myocardial oxygen supply 
during the reperfusion period, thus decreasing the result-
ing myocardial infarct size. Moreover, the preponderance 
of prostaglandins might reduce platelet aggregation,35 
helping to prevent coronary microemboli during reperfu-
sion. Nevertheless, these various effects could have been 
actuated by any available COX inhibitor due to different 
affinities and variety of mechanisms.
Whereas COX-2 is a well-known mediator of early1 
and late ischemic21 and anesthetic-induced22 precondition-
ing, the role of COX-1 is not clear regarding anesthetic-
induced preconditioning. It has been demonstrated that 
COX-1 mediates the delayed phase (after 48 hours) but not 
the early phase (after 24 hours) of morphine-induced 
delayed preconditioning.16 Functional blockade of COX-1 
by SC-560 neither inhibited APOC nor had any additive 
beneficial effect on APOC in the current study. Additionally, 
the beneficial effect of APOC was not altered by pretreat-
ment with acetylsalicylic acid (ASA). Primarily ASA 
inhibits COX-1.36 These results confirm that interference 
between anesthetic-induced preconditioning and COX 
inhibition most likely depends on the COX-2 affinity. 
However, we found no cardioprotective effect of ASA 
itself. This emphasizes the relevance of comedications and 
Figure 3. Sevoflurane-induced postconditioning against 
myocardial infarction is mediated by cyclooxygenase-2 (COX-
2), whereas blockade of cyclooxygenase-1 (COX-1) itself is 
cardioprotective. Myocardial infarct size (IS) expressed as 
percentage of left ventricular area at risk (AAR). Values are 
mean ± SD. n = 7 in each group. *Significantly (P > .05) different 
from CON. Mice received either no intervention (CON), 
dimethyl sulfoxide (DMSO), sevoflurane (SEVO), acetylsalicylic 
acid alone (ASA) or in combination with sevoflurane 
(SEVO+ASA), SC-560 alone (SC-560) or in combination with 
sevoflurane (SEVO+SC-560), or NS-398 alone (NS-398) or in 
combination with sevoflurane (SEVO+NS-398).
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their interference with protective effects subsequent to 
ischemic injury, a topic relevant for several endangered 
tissues, such as the kidney37,38 and liver.39
The results of the current study should be interpreted 
within the constraint of several potential limitations. The 
left ventricular area at risk and the amount of coronary 
collateral blood flow are crucial determinants of myocar-
dial infarct size. However, the area at risk was not differ-
ent among groups. Coronary collateral blood flow was not 
measured in this study. However, rodents are reported to 
have little if any coronary collateral blood flow.40 Thus, it 
is unlikely that AAR and coronary collateral blood flow 
account for the differences in myocardial infarct size. 
Furthermore, triphenyltetrazolium chloride (TTC) stain-
ing was the only indicator of myocardial infarct size. 
Other markers of myocardial injury such as troponin val-
ues were not determined in this study. Alterations in myo-
cardial oxygen supply and demand ratio might have 
affected the observed results. Sevoflurane decreased heart 
rates during early reperfusion in the SEVO and 
SEVO+ASA groups and tended to decrease heart rates in 
the SEVO+SC-560 and SEVO+NS-398 groups. Coronary 
venous oxygen content was not measured, and myocardial 
oxygen consumption was not directly quantified in this 
study. Therefore, we cannot completely exclude that 
changes in myocardial oxygen supply-demand ratio might 
contribute to the infarct size reduction by sevoflurane-
induced postconditioning. It has been shown that SC-560 
at 10 µg/g and NS-398 at 5 µg/g effectively inhibit COX-1 
and COX-2, respectively.16 However, potential effects of 
SC-560 and NS-398 on other proteins involved in the sig-
nal transduction cascade of sevoflurane-induced postcon-
ditioning cannot be excluded.
In summary, the present study demonstrates that the 
in vivo administration of 1.0 MAC sevoflurane during 
early reperfusion induces postconditioning against myo-
cardial infarction in the murine heart. The results further 
indicate that these protective effects are mediated by 
COX-2.
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Figure 4. Representative left ventricular slices of an animal of each experimental group. White colored zones indicate infarcted 
tissue, red colored zones indicate the area at risk (ischemic tissue), and blue colored zones indicate the normal zone (nonischemic 
tissue). ASA, acetylsalicylic acid; CON, control; DMSO, dimethyl sulfoxide; NS-398, cyclooxygenase-2 blocker; SC-560, 
cyclooxygenase-1 blocker; SEVO, sevoflurane.
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